Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Pharmaceuticals (NASDAQ: BLCM) announced equity inducement grants of 13,680 stock options to three new employees on August 31, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bellicum Pharmaceuticals (NASDAQ: BLCM) announced equity inducement grants of 13,680 stock options to three new employees on August 31, 2020. The grants were approved by the Compensation Committee as part of Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $5.95 per share, vesting over four years, with 25% vesting on the first anniversary and monthly thereafter, contingent upon continued employment. The options fall under the company's 2019 Equity Incentive Plan.
Positive
- Inducement grants of stock options may attract skilled employees.
- Stock options have a favorable exercise price of $5.95, potentially aligning employee interests with shareholder value.
Negative
- None.
Details
News Market Reaction – BLCM
The recorded move for BLCM in the trading session of this news was -9.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to three new employees consisting of an aggregate of 13,680 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of August 31, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and CAR-NK cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.